Revenue
2020
2021
2022
2023
2024
2025
Atea Pharmaceuticals, Inc. (AVIR)
Price$5.79Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $351.4M | $48.6M | — | — |
| Research & development | $148.0M | $144.1M | $114.2M | $81.9M | $167.2M | $38.0M | $10.2M | $6.7M |
| Operating expenses | $180.9M | $192.9M | $164.2M | $130.7M | $213.0M | $59.7M | $14.6M | $9.5M |
| Operating income | −$180.9M | −$192.9M | −$164.2M | −$130.7M | $138.4M | −$11.0M | −$14.6M | −$9.5M |
| Operating margin | — | — | — | — | 39.38% | −22.68% | — | — |
| EBITDA | −$180.5M | −$192.5M | −$163.7M | −$130.4M | $138.4M | −$11.0M | −$14.6M | −$9.5M |
| EBITDA margin | — | — | — | — | 39.39% | −22.64% | — | — |
| Net income | −$158.3M | −$168.4M | −$136.0M | −$115.9M | $121.2M | −$10.9M | −$14.0M | −$9.1M |
| Net profit margin | — | — | — | — | 34.49% | −22.51% | — | — |
| Basic EPSper basic share | -$1.94 | -$2.00 | -$1.63 | -$1.39 | $1.46 | -$0.51 | -$1.39 | -$0.90 |
| Diluted EPSper diluted share | -$1.94 | -$2.00 | -$1.63 | -$1.39 | $1.37 | -$0.51 | -$1.39 | -$0.90 |
Owners
Reported shareholders
14.97%of listed shares
FMR LLC12M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 14.97%12M shares |
BlackRock, Inc. | 10.87%8.72M shares |
BML Capital Management, LLC | 8.67%6.95M shares |
Sommadossi Jean-Pierre | ≈8.27%6.63M shares |
TANG CAPITAL MANAGEMENT LLC | 6.00%4.81M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.70%2.96M shares |
Bain Capital Life Sciences Investors, LLC | 2.59%2.08M shares |
ACADIAN ASSET MANAGEMENT LLC | 2.54%2.04M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.44%1.96M shares |
STATE STREET CORP | 2.06%1.65M shares |
TWO SIGMA INVESTMENTS, LP | 1.88%1.51M shares |
DIMENSIONAL FUND ADVISORS LP | 1.62%1.3M shares |
RENAISSANCE TECHNOLOGIES LLC | 1.41%1.13M shares |
Rosalind Advisors, Inc. | 1.33%1.07M shares |
JPMORGAN CHASE & CO | 1.18%945.92K shares |
Corcoran Andrea | ≈1.03%823.58K shares |
NORTHERN TRUST CORP | 0.94%755.24K shares |
MORGAN STANLEY | 0.90%719.51K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.79%630.19K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.76%610.61K shares |
Percentages use 80.2M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4/A | Murphy Polly A.Director | BuyCommon Stock | 6.1K | $4.17 | $25.4K | 92.1K |
| May 18, 2025Form 4 | Murphy Polly A.Director | BuyCommon Stock | 6.1K | $4.17 | $25.4K | 92.1K |
| Jan 16, 2025Form 4/A | BERGER FRANKLIN MDirector | BuyCommon Stock | 10.0K | $3.36 | $33.6K | 476.9K |
| Jan 16, 2025Form 4 | BERGER FRANKLIN MDirector | BuyCommon Stock | 10.0K | $3.36 | $33.6K | 476.9K |
| Jan 15, 2025Form 4/A | BERGER FRANKLIN MDirector | BuyCommon Stock | 15.0K | $3.19 | $47.9K | 466.9K |